Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 2
1981 1
1982 1
1983 5
1984 2
1985 8
1986 11
1987 3
1988 9
1989 10
1990 4
1991 8
1992 13
1993 10
1994 6
1995 11
1996 13
1997 22
1998 8
1999 13
2000 16
2001 16
2002 21
2003 23
2004 29
2005 26
2006 23
2007 18
2008 25
2009 21
2010 15
2011 31
2012 23
2013 29
2014 37
2015 32
2016 22
2017 21
2018 26
2019 22
2020 26
2021 28
2022 11
2023 13
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

655 results

Results by year

Filters applied: . Clear all
Page 1
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
Bornstein SR, de Zeeuw D, Heerspink HJL, Schulze F, Cronin L, Wenz A, Tuttle KR, Hadjadj S, Rossing P. Bornstein SR, et al. Among authors: de zeeuw d. Diabetes Obes Metab. 2024 Jun;26(6):2128-2138. doi: 10.1111/dom.15518. Epub 2024 Mar 18. Diabetes Obes Metab. 2024. PMID: 38497241 Clinical Trial.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group. Tuttle KR, et al. Among authors: de zeeuw d. Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.
Regional Variation in Hemoglobin Distribution Among Individuals With CKD: the ISN International Network of CKD Cohorts.
Canney M, Induruwage D, Tang M, Alencar de Pinho N, Er L, Zhao Y, Djurdjev O, Ahn YH, Behnisch R, Calice-Silva V, Chesnaye NC, de Borst MH, Dember LM, Dionne J, Ebert N, Eder S, Fenton A, Fukagawa M, Furth SL, Hoy WE, Imaizumi T, Jager KJ, Jha V, Kang HG, Kitiyakara C, Mayer G, Oh KH, Onu U, Pecoits-Filho R, Reichel H, Richards A, Schaefer F, Schaeffner E, Scheppach JB, Sola L, Ulasi I, Wang J, Yadav AK, Zhang J, Feldman HI, Taal MW, Stengel B, Levin A; ISN iNET-CKD Investigators. Canney M, et al. Kidney Int Rep. 2023 Aug 12;8(10):2056-2067. doi: 10.1016/j.ekir.2023.07.032. eCollection 2023 Oct. Kidney Int Rep. 2023. PMID: 37850014 Free PMC article.
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
Smeijer JD, Kohan DE, Rossing P, Correa-Rotter R, Liew A, Tang SCW, de Zeeuw D, Gansevoort RT, Ju W, Lambers Heerspink HJ. Smeijer JD, et al. Among authors: de zeeuw d. Cardiovasc Diabetol. 2023 Sep 16;22(1):251. doi: 10.1186/s12933-023-01964-8. Cardiovasc Diabetol. 2023. PMID: 37716952 Free PMC article.
The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
Yu J, Sweeting AN, Gianacas C, Houston L, Lee V, Fletcher RA, Perkovic V, Li Q, Neuen BL, Berwanger O, Heerspink HJL, de Zeeuw D, Arnott C. Yu J, et al. Among authors: de zeeuw d. Diabetes Obes Metab. 2023 Dec;25(12):3724-3735. doi: 10.1111/dom.15267. Epub 2023 Sep 6. Diabetes Obes Metab. 2023. PMID: 37671609
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Chan KW, Smeijer JD, Schechter M, Jongs N, Vart P, Kohan DE, Gansevoort RT, Liew A, Tang SCW, Wanner C, de Zeeuw D, Heerspink HJL. Chan KW, et al. Among authors: de zeeuw d. Kidney Int. 2023 Dec;104(6):1219-1226. doi: 10.1016/j.kint.2023.08.014. Epub 2023 Aug 31. Kidney Int. 2023. PMID: 37657768 Free article. Clinical Trial.
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.
Charytan DM, Mahaffey KW, Jardine MJ, Cannon CP, Neal B, Lambers Heerspink HJ, Agarwal R, Bakris GL, de Zeeuw D, Levin A, Pollock C, Zhang H, Zinman B, Rosenthal N, Perkovic V, Di Tanna GL, Yu J, Rogers K, Arnott C, Wheeler DC. Charytan DM, et al. Among authors: de zeeuw d. BMJ Open Diabetes Res Care. 2023 Jun;11(3):e003270. doi: 10.1136/bmjdrc-2022-003270. BMJ Open Diabetes Res Care. 2023. PMID: 37311602 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
Cherney DZI, de Zeeuw D, Heerspink HJL, Cardona J, Desch M, Wenz A, Schulze F, Nangaku M. Cherney DZI, et al. Among authors: de zeeuw d. Diabetes Obes Metab. 2023 Aug;25(8):2218-2226. doi: 10.1111/dom.15099. Epub 2023 May 25. Diabetes Obes Metab. 2023. PMID: 37232058 Clinical Trial.
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, Arnott C, Hockham C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Mahaffey KW, Perkovic V, Jardine MJ. Kang A, et al. Among authors: de zeeuw d. Diabetes Obes Metab. 2023 Aug;25(8):2151-2162. doi: 10.1111/dom.15091. Epub 2023 May 10. Diabetes Obes Metab. 2023. PMID: 37161691 Clinical Trial.
655 results